<DOC>
	<DOC>NCT01981109</DOC>
	<brief_summary>The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.</brief_summary>
	<brief_title>A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Written informed consent obtained prior to the initiation of study procedures. Men ≥ 18 years of age. Histologically documented prostatic adenocarcinoma. History of CastrationResistant Prostate Cancer. Known M1 disease. Undergone imaging study for metastatic prostate cancer ≤ 3 months. ECOG performance status ≥ 3. Known malignant pleural effusions or ascites. Current or prior treatment with investigational therapy for M0 CastrationResistant Prostate Cancer (Taxotere (docetaxel), Provenge® (sipuleucelT), Zytiga (abiraterone acetate), Xtandi (enzalutamide), Jevtana (cabazitaxel), or Xofigo (radium Ra 223 dichloride).</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>